Screener
aTyr Pharma ATYR Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $6,748 | $15,384 | 14,065 | 27,198 |
| General and administrative | 4,133 | 4,929 | 8,252 | 8,888 |
| Total operating expenses | 10,881 | 20,313 | 22,317 | 36,086 |
| Loss from operations | (10,881) | (20,313) | (22,317) | (36,086) |
| Total other income (expense), net | 571 | 781 | 1,215 | 1,673 |
| Consolidated net loss | (10,310) | (19,532) | (21,102) | (34,413) |
| Net loss attributable to noncontrolling interest in Pangu BioPharma Limited | 1 | 1 | 2 | 2 |
Item 1. Financial Statements
FAQ
- What is aTyr Pharma's total operating expenses?
- aTyr Pharma (ATYR) reported total operating expenses of $10.88M in Q2 2026.
- How has aTyr Pharma's total operating expenses changed year-over-year?
- aTyr Pharma's total operating expenses decreased by 46.4% year-over-year, from $20.31M to $10.88M.
- What is the long-term trend for aTyr Pharma's total operating expenses?
- Over 4 years (2021 to 2025), aTyr Pharma's total operating expenses has grown at a 23.0% compound annual growth rate (CAGR), from $34.02M to $77.82M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about aTyr Pharma's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude